Louise Moist, MD
Moist L. In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization. Ann Intern Med. ;168:JC52. doi: 10.7326/ACPJC-2018-168-10-052
Download citation file:
Published: Ann Intern Med. 2018;168(10):JC52.
Cardiology, Coronary Risk Factors, Diabetes, Diabetic Nephropathy, Endocrine and Metabolism.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use